3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
25
Pancreatic Neoplasms
19
Neoplasm Metastasis
17
Neuroblastoma
8
Lung Neoplasms
6
Rhabdomyosarcoma
5
Rectal Neoplasms
5
Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Colonic Neoplasms
5
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Sarcoma, Ewing
4
Sarcoma
4
Esophageal Neoplasms
4
Adenocarcinoma Of Esophagus
4
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Biliary Tract Neoplasms
3
Wilms Tumor
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Kidney Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Glioma
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Melphalan
3
pembrolizumab
2
obinutuzumab
2
blinatumomab
2
Rituximab
2
Radiotherapy
2
Lenalidomide
2
Capecitabine
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
sacituzumab govitecan
1
palbociclib
1
nilotinib
1
isatuximab
1
avelumab
1
atezolizumab
1
acalabrutinib
1
Whole-Body Irradiation
1
Trastuzumab
1
Sirolimus
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Irinotecan
×
90 days
×
Clear all
No trials found.